Literature DB >> 28095113

Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins.

Juliane Kums1, Johannes Nelke1, Benedikt Rüth1, Viktoria Schäfer1, Daniela Siegmund1, Harald Wajant1.   

Abstract

Cell surface antigen-specific antibodies are of substantial diagnostic and therapeutic importance. The binding properties of such antibodies are usually evaluated by cell-free assays, in particular surface plasmon resonance (SPR) analysis, or flow cytometry. SPR analyses allow the detailed quantitative and dynamic evaluation of the binding properties of antibodies, but need purified, typically recombinantly produced antigens. It can, however, be difficult to produce the required antigen. Furthermore, cellular factors influencing the antigen-antibody interaction are not considered by this method. Flow cytometry-based analyses do not have these limitations, but require elaborated calibration controls for absolute quantification of bound molecules. To overcome the limitations of SRP and flow cytometry in the characterization of cell surface antigen-specific antibodies, we developed Fn14-specific antibody 18D1 as an example of an antibody fusion protein format that includes the luciferase of Gaussia princeps (GpL), which enables very simple and highly sensitive cellular binding studies. We found that GpL-tagging of the C-terminus of the antibody light chain does not affect the interaction of 18D1-IgG1 with its antigen and Fc-gamma receptors (FcγRs). In accordance with this, the GpL(LC-CT)-18D1-IgG1 antibody fusion protein showed basically the same FcγR-dependent agonistic properties as the parental 18D1 antibody. Similar results were obtained with isotype switch variants of 18D1 and antibodies specific for CD95, LTβR and CD40. In sum, we demonstrate that antibody GpL fusion proteins are easily manageable and versatile tools for the characterization of cell surface antigen-antibody interactions that have the potential to considerably extend the instrumentarium for the evaluation of antibodies.

Entities:  

Keywords:  Antibody; Fn14; Gaussia princeps luciferase; TWEAK; cellular binding studies

Mesh:

Substances:

Year:  2017        PMID: 28095113      PMCID: PMC5384709          DOI: 10.1080/19420862.2016.1274844

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  26 in total

1.  Fluorescent Citrine-IgG fusion proteins produced in mammalian cells.

Authors:  Alexander K Haas; Christoffer von Schwerin; Daniela Matscheko; Ulrich Brinkmann
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

Review 2.  Biopharmaceutical production: Applications of surface plasmon resonance biosensors.

Authors:  Pranavan Thillaivinayagalingam; Julien Gommeaux; Michael McLoughlin; David Collins; Anthony R Newcombe
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-09-01       Impact factor: 3.205

Review 3.  Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions.

Authors:  David J DiLillo; Jeffrey V Ravetch
Journal:  Cancer Immunol Res       Date:  2015-07       Impact factor: 11.151

4.  TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB.

Authors:  P Schneider; M Thome; K Burns; J L Bodmer; K Hofmann; T Kataoka; N Holler; J Tschopp
Journal:  Immunity       Date:  1997-12       Impact factor: 31.745

5.  Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand.

Authors:  Agnes Wyzgol; Nicole Müller; Andrea Fick; Sabine Munkel; Goetz Ulrich Grigoleit; Klaus Pfizenmaier; Harald Wajant
Journal:  J Immunol       Date:  2009-07-13       Impact factor: 5.422

6.  Soluble TL1A is sufficient for activation of death receptor 3.

Authors:  Sebastian Bittner; Gertrud Knoll; Simone Füllsack; Maria Kurz; Harald Wajant; Martin Ehrenschwender
Journal:  FEBS J       Date:  2015-11-24       Impact factor: 5.542

7.  A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency.

Authors:  M Chodorge; S Züger; C Stirnimann; C Briand; L Jermutus; M G Grütter; R R Minter
Journal:  Cell Death Differ       Date:  2012-01-20       Impact factor: 15.828

8.  CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.

Authors:  J Trebing; M El-Mesery; V Schäfer; D Weisenberger; D Siegmund; K Silence; H Wajant
Journal:  Cell Death Dis       Date:  2014-01-30       Impact factor: 8.469

Review 9.  Site-Specifically Labeled Immunoconjugates for Molecular Imaging--Part 1: Cysteine Residues and Glycans.

Authors:  Pierre Adumeau; Sai Kiran Sharma; Colleen Brent; Brian M Zeglis
Journal:  Mol Imaging Biol       Date:  2016-02       Impact factor: 3.488

10.  CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells.

Authors:  M El-Mesery; J Trebing; V Schäfer; D Weisenberger; D Siegmund; H Wajant
Journal:  Cell Death Dis       Date:  2013-11-14       Impact factor: 8.469

View more
  5 in total

1.  Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors.

Authors:  Simon Sirtl; Gertrud Knoll; Dieu Thuy Trinh; Isabell Lang; Daniela Siegmund; Stefanie Gross; Beatrice Schuler-Thurner; Patrick Neubert; Jonathan Jantsch; Harald Wajant; Martin Ehrenschwender
Journal:  Oncogene       Date:  2018-04-30       Impact factor: 9.867

2.  Membrane lymphotoxin-α2β is a novel tumor necrosis factor (TNF) receptor 2 (TNFR2) agonist.

Authors:  Kirstin Kucka; Isabell Lang; Tengyu Zhang; Daniela Siegmund; Juliane Medler; Harald Wajant
Journal:  Cell Death Dis       Date:  2021-04-06       Impact factor: 8.469

3.  CD40- and 41BB-specific antibody fusion proteins with PDL1 blockade-restricted agonism.

Authors:  Juliane Medler; Kirstin Kucka; Vinicio Melo; Tengyu Zhang; Stefan von Rotenhan; Jakob Ulrich; Edwin Bremer; Michael Hudecek; Andreas Beilhack; Harald Wajant
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.556

4.  A TNFR2-Specific TNF Fusion Protein With Improved In Vivo Activity.

Authors:  Juan Gamboa Vargas; Jennifer Wagner; Haroon Shaikh; Isabell Lang; Juliane Medler; Mohamed Anany; Tim Steinfatt; Josefina Peña Mosca; Stephanie Haack; Julia Dahlhoff; Maike Büttner-Herold; Carolin Graf; Estibaliz Arellano Viera; Hermann Einsele; Harald Wajant; Andreas Beilhack
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

5.  CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.

Authors:  Johannes Nelke; Juliane Medler; Daniela Weisenberger; Andreas Beilhack; Harald Wajant
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.